Coverage
-
July 05, 2017
A New Jersey federal judge has blocked HQ Specialty Pharma Corp. from seeking the U.S. Food and Drug Administration's approval for a new generic version of Baxter Healthcare Corp.'s antiarrhythmic drug Brevibloc, ruling the action would violate an earlier settlement resolving patent infringement allegations.
3 other articles on this case.
View all »